SG11201900078SA - Methods of diagnosis and treatment of pre-eclampsia - Google Patents

Methods of diagnosis and treatment of pre-eclampsia

Info

Publication number
SG11201900078SA
SG11201900078SA SG11201900078SA SG11201900078SA SG11201900078SA SG 11201900078S A SG11201900078S A SG 11201900078SA SG 11201900078S A SG11201900078S A SG 11201900078SA SG 11201900078S A SG11201900078S A SG 11201900078SA SG 11201900078S A SG11201900078S A SG 11201900078SA
Authority
SG
Singapore
Prior art keywords
international
eclampsia
singapore
treatment
immunos
Prior art date
Application number
SG11201900078SA
Inventor
Bruno Reversade
Lena Wai Mun Ho
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201900078SA publication Critical patent/SG11201900078SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111110111001111101100111110111101111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/013053 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, A61K 38/22 (2006.01) CO7K 14/575 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, G01N 33/74 (2006.01) A61P 43/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/SG2017/050321 KR, MG, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 28 June 2017 (28.06.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 10201605841S 15 July 2016 (15.07.2016) SG UG, TM), ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, #20-10 Connexis, Singapore 138632 (SG). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: REVERSADE, Bruno; c/o Institute of Medical KM, ML, MR, NE, SN, TD, TG). Biology, 8A Biomedical Grove, #05-40 Immunos, Singa- — pore 138648 (SG). HO, Lena Wai Mun; c/o Institute of Published: Medical Biology, 8A Biomedical Grove, #05-40 Immunos, — with international search report (Art. 21(3)) Singapore 138648 (SG). — with sequence listing part of description (Rule 5.2(a)) = Agent: KHOO, Chong-Yee; Cantab IP Pte Ltd, VBox = (74) 881846, Singapore 919191 (SG). = Designated States (unless otherwise indicated, for every = (81) kind of national protection available): AE, AG, AL, AM, = (54) Title: METHODS OF DIAGNOSIS AND TREATMENT OF PRE-ECLAMPSIA FIGURE 3 (57) : The invention relates to an ELABELA polypeptide or = nucleic acid for use in the treatment, alleviation or prophylaxis of pre- eclampsia in an individual. In another aspect of the invention, there is pro- vided a method of diagnosing or detecting the susceptibility of an indi- = :11 11 -. • vidual to pre-eclampsia, wherein the method comprises detecting modu- IELABELA. f lation, preferably down -regulation of expression, amount or activity of = — = = . ,. = _ = = ' — 1-1 gr. LA • lin M 3 © . Cr) Il © . . . • . . . . .. 8 - 1 © ei NP NOmlal PE C
SG11201900078SA 2016-07-15 2017-06-28 Methods of diagnosis and treatment of pre-eclampsia SG11201900078SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201605841S 2016-07-15
PCT/SG2017/050321 WO2018013053A1 (en) 2016-07-15 2017-06-28 Methods of diagnosis and treatment of pre-eclampsia

Publications (1)

Publication Number Publication Date
SG11201900078SA true SG11201900078SA (en) 2019-02-27

Family

ID=60953231

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900078SA SG11201900078SA (en) 2016-07-15 2017-06-28 Methods of diagnosis and treatment of pre-eclampsia

Country Status (5)

Country Link
US (1) US20200179487A1 (en)
EP (1) EP3484501A4 (en)
CN (1) CN109922823A (en)
SG (1) SG11201900078SA (en)
WO (1) WO2018013053A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108776226B (en) * 2018-04-08 2021-03-19 邓成 Test paper and kit for rapidly screening early-stage eclampsia
CN116617368A (en) * 2023-05-30 2023-08-22 杭州师范大学 Application of Elabela in vascular endothelial cell aging resistance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105612174A (en) * 2013-07-25 2016-05-25 诺华股份有限公司 Disulfide cyclic polypeptides for the treatment of heart failure
US9309314B2 (en) * 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
EP3206707B1 (en) * 2014-10-13 2020-12-02 University of Maryland, Baltimore Fc-ela-32 and its use in the treatment of cardiac conditions

Also Published As

Publication number Publication date
WO2018013053A1 (en) 2018-01-18
US20200179487A1 (en) 2020-06-11
CN109922823A (en) 2019-06-21
EP3484501A4 (en) 2020-03-11
WO2018013053A9 (en) 2018-02-08
EP3484501A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201908391XA (en) Methods for modulating an immune response
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201811432WA (en) Rna for cancer therapy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201807912SA (en) Vaccine against rsv
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201900400QA (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201901351UA (en) A patient interface, system and method
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201808539WA (en) Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805755SA (en) Methods of administering hepcidin
SG11201810670VA (en) Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma
SG11201909107YA (en) Stenosis treatment
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof